Disease · HP_0100806
Comparisons in its trials90
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 90
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| ART-123 vs Placebo: Number of Participants With Anti-drug Antibodies | 0 of 396 | 0 of 404 | 800 | NCT01598831 | Trial comparisons |
| ART-123 vs Placebo: Follow up All-cause Mortality at 3 Months | 126 of 395 | 136 of 405 | 800 | NCT01598831 | Trial comparisons |
| ART-123 vs Placebo: Number of Participants With On-Treatment Serious Major Bleeding Events | 23 of 396 | 16 of 404 | 800 | NCT01598831 | Trial comparisons |
| ART-123 vs Placebo: deaths from any cause | 141 of 395 | 148 of 405 | 800 | NCT01598831 | Trial comparisons |
| ART-123 vs Placebo: Number of Participants With 28-Day All-cause Mortality | 106 of 395 | 119 of 405 | 800 | NCT01598831 | Trial comparisons |
| ART-123 vs Placebo: serious adverse events | 206 of 396 | 202 of 404 | 800 | NCT01598831 | Trial comparisons |
| ART-123 vs Placebo: Day 28 Mortality in Subjects With INR > 1.4 at Baseline and PLT > 30K at Baseline | 82 of 307 | 105 of 327 | 634 | NCT01598831 | Trial comparisons |
| Treatment Protocol vs Control Protocol: Intensive Care Unit (ICU) Mortality | 52 of 252 | 49 of 249 | 501 | NCT03509350 | Trial comparisons |
| Treatment Protocol vs Control Protocol: Mortality at 30 Days | 56 of 252 | 60 of 249 | 501 | NCT03509350 | Trial comparisons |
| Treatment Protocol vs Control Protocol: deaths from any cause | 102 of 252 | 94 of 249 | 501 | NCT03509350 | Trial comparisons |
| Treatment Protocol vs Control Protocol: Mortality at 180 Days | 102 of 252 | 94 of 249 | 501 | NCT03509350 | Trial comparisons |
| Treatment Protocol vs Control Protocol: serious adverse events | 0 of 252 | 0 of 249 | 501 | NCT03509350 | Trial comparisons |
| Standard Therapy vs Alternative Therapy: serious adverse events | 33 of 250 | 48 of 236 | 486 | NCT00386425 | Trial comparisons |
| Dexmedetomidine vs Propofol: Death at 90 Days | 81 of 214 | 82 of 208 | 422 | NCT01739933 | Trial comparisons |
| Dexmedetomidine vs Propofol: deaths from any cause | 89 of 214 | 86 of 208 | 422 | NCT01739933 | Trial comparisons |
| Dexmedetomidine vs Propofol: serious adverse events | 0 of 214 | 0 of 208 | 422 | NCT01739933 | Trial comparisons |
Intermittent. Piperacillin/Tazobactam, Imipenem, Meropenem vs Prolonged Infusion. Continuous Piperacillin/Tazobactam, Extended Imipenem, Extended Meropenem: Number of Participants With Clinical Response | 178 of 201 | 169 of 202 | 403 | NCT03019965 | Trial comparisons |
| Intermittent. Piperacillin/Tazobactam, Imipenem, Meropenem vs Prolonged Infusion. Continuous Piperacillin/Tazobactam, Extended Imipenem, Extended Meropenem: Number of Participants With Adverse Events | 1 of 201 | 3 of 202 | 403 | NCT03019965 | Trial comparisons |
| Intermittent. Piperacillin/Tazobactam, Imipenem, Meropenem vs Prolonged Infusion. Continuous Piperacillin/Tazobactam, Extended Imipenem, Extended Meropenem: deaths from any cause | 17 of 201 | 19 of 202 | 403 | NCT03019965 | Trial comparisons |
| Intermittent. Piperacillin/Tazobactam, Imipenem, Meropenem vs Prolonged Infusion. Continuous Piperacillin/Tazobactam, Extended Imipenem, Extended Meropenem: serious adverse events | 0 of 201 | 0 of 202 | 403 | NCT03019965 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/HP_0100806/comparisons